Floatz logo

Cetuximab

BRAF NP_004324.2:p.V600E

M.D. Anderson Cancer Centermonoclonal_antibodyPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the BRAF NP_004324.2:p.V600E cohort.

Asset / SponsorPhaseRating
Encorafenib
M.D. Anderson Cancer Center
Phase 1/2CCC
Nivolumab
M.D. Anderson Cancer Center
Phase 1/2CCC

Same molecule, other indications

Cetuximab is also rated in:

colon adenocarcinomaDormant
BB
Indicative ·
70 / 100
View asset →
colorectal cancerDormant
BB
Indicative ·
70 / 100
View asset →
rectal carcinomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →